PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY
(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

CODE	DATE	NTD

ANKOM 04 JUL 2005 GIPS

DATA ENTERED

FINAL CHECK

Applicant's or agent's file reference	FOR FURTHER ACTION	See Form PCT/IPEA/416
100949-1 WO		

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/SE2004/000450	23.03.2004	25.03.2003

International Patent Classification (IPC) or national classification and IPC

C07D 401/06, C07D 401/14, A61K 31/4545, A61P 11/00, A61P 17/00, A61P 19/00, A61P 29/00, A61P 37/00

Applicant

AstraZeneca AB et al

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets, including this cover sheet.
3. This report is also accompanied by ANNEXES, comprising:

   a. ☐ *(sent to the applicant and to the International Bureau)* a total of _____ sheets, as follows:

      ☐ sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).

      ☐ sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.

   b. ☐ *(sent to the International Bureau only)* a total of (indicate type and number of electronic carrier(s))

      _____, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).

4. This report contains indications relating to the following items:

☒	Box No. I	Basis of the report
☐	Box No. II	Priority
☒	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
☐	Box No. IV	Lack of unity of invention
☒	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
☐	Box No. VI	Certain documents cited
☐	Box No. VII	Certain defects in the international application
☐	Box No. VIII	Certain observations on the international application

Date of submission of the demand	Date of completion of this report
06.10.2004	23.06.2005
Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. +46 8 667 72 88	Authorized officer Johanna Brolund/ELY Telephone No. +46 8 782 25 00

Form PCT/IPEA/409 (cover sheet) (January 2004)

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/SE2004/000450

Box No. I Basis of the report

1. With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ This report is based on a translation from the original language into the following language _____, which is the language of a translation furnished for the purposes of:

☐ international search (under Rules 12.3 and 23.1(b))
☐ publication of the international application (under Rule 12.4)
☐ international preliminary examination (under Rules 55.2 and/or 55.3)

2. With regard to the elements of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):*

☒ the international application as originally filed/furnished

☐ the description:

pages _____ as originally filed/furnished
pages* _____ received by this Authority on _____
pages* _____ received by this Authority on _____

☐ the claims:

pages _____ as originally filed/furnished
pages* _____ as amended (together with any statement) under Article 19
pages* _____ received by this Authority on _____
pages* _____ received by this Authority on _____

☐ the drawings:

pages _____ as originally filed/furnished
pages* _____ received by this Authority on _____
pages* _____ received by this Authority on _____

☐ a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing.

3. ☐ The amendments have resulted in the cancellation of:

☐ the description, pages _____
☐ the claims, Nos. _____
☐ the drawings, sheets/figs _____
☐ the sequence listing *(specify)*: _____
☐ any table(s) related to the sequence listing *(specify)*: _____

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

☐ the description, pages _____
☐ the claims, Nos. _____
☐ the drawings, sheets/figs _____
☐ the sequence listing *(specify)*: _____
☐ any table(s) related to the sequence listing *(specify)*: _____

* *If item 4 applies, some or all of those sheets may be marked "superseded."*

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/SE2004/000450

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application

☒ claims Nos. 11

because:

☒ the said international application, or the said claims Nos. 11
relate to the following subject matter which does not require an international preliminary examination *(specify)*:

Claim 11 relates to a method of treatment of the human body by surgery or by therapy. See PCT Rule 67.1.(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

☐ the description, claims or drawings *(indicate particular elements below)* or said claims Nos. _____
are so unclear that no meaningful opinion could be formed *(specify)*:

☐ the claims, or said claims Nos. _____ are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for said claims Nos. _____

☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:

the written form
- ☐ has not been furnished
- ☐ does not comply with the standard

the computer readable form
- ☐ has not been furnished
- ☐ does not comply with the standard

☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in the Annex C-*bis* of the Administrative Instructions.

☐ See Supplemental Box for further details.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/SE2004/000450

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-10	YES
	Claims		NO
Inventive step (IS)	Claims		YES
	Claims	1-10	NO
Industrial applicability (IA)	Claims	1-10	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

The following documents are cited in the International Search Report:

D1: WO 0035877 A1
D2: WO 0177101 A1
D3: GB 1250719 A

The present application according to claims 1-11 relates to piperidine derivatives having activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR3) activity. These compounds may be used in the treatment of autoimmune, inflammatory, proliferative, hyperproliferative or immunologically-related diseases, such as for instance asthma and rhinitis. The application also relates to a process for preparing the compounds, pharmaceutical compositions comprising the compounds and method of treating a chemokine mediated disease state using the compound.

D1 and D2 relates to compounds that are structurally similar to the compound according to the present application and have pharmaceutical activity at chemokine receptors, especially CCR3. The compounds according to formula (I) of the present application and the general formula in D1, claim 1, does not differ, but all the examples of table 1 of D1 comprises an amine group where X is situated in formula (I) of the present application. X is not an amine group. The difference between the general formula (I) of the application and the general formula of D2 is the methyl group between the piperidines of formula (I) which corresponds to a bond in D2.

.../...

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.
Continuation of: Box V

D3 relates to compounds structurally related to the compound of the present application, but with another field of application.

Compounds that are structurally similar to the compounds of claims 1-6 of the present application and have the same field of application are thus known through D1 and D2. To modify the compounds of these documents so as to obtain the compounds according to the present application and to use these compounds in similar ways is considered to be obvious to the person skilled in the art. Thus, claims 1-6 of the present application lack inventive step compared to D1 or D2.

In order to justify the patentability of the present subject-matter, the technical effect of the claimed compounds must be shown. This can, for example, be done by comparative experiments, showing that the compounds according to the claims have such unexpected and beneficial effects, compared to the previously known similar compounds, that they can be considered to differ essentially from said compounds. In order for a compound to be considered patentable, this difference must be shown to result in a novel and unexpected technical effect. The applicant has not indicated any difference in relation to prior art and the significance of such a difference for the whole of the scope of the claims.

The embodiments of claims 7-10 do not differ significantly from what is previously known from the cited documents and are obvious to the person skilled in the art. Therefore, these claims lack inventive step.